Axsome Therapeutics
AXSM
NASDAQ
IPO2015
about AXSM
Axsome Therapeutics is a biopharmaceutical company focused on developing innovative therapies for central nervous system disorders, with its lead product candidate AXSM-95264 targeting major depressive disorder through a novel 5-HT2B receptor agonist mechanism.
| type | open | high | low |
market cap |
volume |
|---|---|---|---|---|---|
| stock | $186.00 | $186.00 | $181.50 | $9.3B | 573.87K |
| eps |
price to earnings |
price to sales |
operating margin |
profit margin |
yield |
| -$0.94 | n/a | 53.83 | -26.97% | -27.62% | 0% |